Report: Walgreens to offer genetic test kits
DEERFIELD, Ill. Walgreens soon will begin selling genetic test kits that may help customers learn more about their risk levels for various diseases, according to a report Monday in The New York Times.
The tests, which measure genetic markers for such potential conditions as diabetes and cancer, are marketed by Pathway Genomics. The company said its test kits likely will be sold in many of Walgreens’ more than 7,500 drug stores, the Times reported.
The DNA tests are based on patients’ saliva samples, according to the report, and will be conducted by outside laboratories. Users will pay as much as $250 or more for the Pathway sample kit sold in the stores and a full set of lab analyses, according to the report.
Winn-Dixie enables customers to help fishermen affected by oil spill
NEW ORLEANS People wanting to help the Louisiana fishermen affected by the Deepwater Horizon oil spill off the Gulf Coast can do so when they buy groceries at any of the 36 neighborhood Winn-Dixie Stores in the New Orleans area, the grocer announced Friday.
Winn-Dixie has implemented its “Neighbors Helping Neighbors” program, a convenient way customers can donate any amount between $0.50 and $500 directly to the United Way of Greater New Orleans as they pay for their groceries. The cashier will scan a special Neighbors Helping Neighbors bar code, which automatically adds the amount designated by the customer to the total bill.
The United Way of Greater New Orleans is assisting the fishermen of St. Bernard and Plaquemines Parishes by providing food, counseling and other assistance to the fishing communities in Louisiana’s Mississippi River Delta affected by the oil spill in the Gulf of Mexico.
Winn-Dixie announced the program on Friday when the grocer and several of its vendor partners delivered three semi-trailers loaded with 42,000 lbs. of food and 28,800 gallons of bottled water to the Second Harvest Food Bank for distribution to food banks serving the two Mississippi River delta parishes.
Actavis, Sagent partner to develop and market injectable drugs
MORRISTOWN, N.J. Actavis and Sagent Pharmaceuticals have agreed to develop and market a group of injectable drugs in the United States, Actavis announced.
Under the agreement, Actavis will develop the drugs, seek Food and Drug Administration approval for them and supply them, while Sagent will market them. Financial terms of the deal were not disclosed.
“Actavis’ impressive injectable pipeline, substantial development and supply capabilities and excellent record of execution make Actavis an outstanding partner Sagent,” Sagent CEO and board chairman Jeffrey Yordon said in a statement. “This collaboration complements Sagent’s strategy by quickly adding products to our marketed portfolio, and we look forward to working with Actavis to expand our collective portfolio.”